This content is in French.
Capivasertib + Fulvestrant: the right choice after CDK4/6 inhibitor failure?
17 octobre 2025
By Ana Espino | Published on October 17, 2025 | 3 min readMetastatic HR+/HER2– breast cancer — the most common subtype in postmenopausal women — remains an incurable disease despite advances in endocrine therapy and CDK4/6 inhibitors. Most patients eventually develop secondary resistance, limiting therapeutic options. Alterations in the PI3K/AKT/PTEN pathway, frequently observed in this subtype, c
Metastatic HR+/HER2– breast cancer — the most common subtype in postmenopausal women — remains an incurable disease despite advances in endocrine therapy and CDK4/6 inhibitors. Most patients eventually develop secondary resistance, limiting therapeutic options. Alterations in the PI3K/AKT/PTEN pathway, frequently observed in this subtype, contribute to resistance and represent a promising therapeutic target.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Aboud, K., et al. (2025). Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer. Therapeutic advances in medical oncology, 17, 17588359251358947
View the source
